Please login to the form below
Gene testing
This page shows the latest Gene testing news and features for those working in and with pharma, biotech and healthcare.
AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
As part of this first deal, Voyager received $69m upfront to advance gene therapy candidates into phase 1 testing, with AbbVie gaining the option to license one or more for further ... In 2019, French drugmaker Sanofi also scaled back on a gene therapy
Latest news
-
Astellas makes gene therapy a core focus with $3bn Audentes buy
Meanwhile, Audentes has several other candidates in development, including therapies for Pompe disease, Duchenne muscular dystrophy and myotonic dystrophy that are being prepared for clinical testing. ... It’s not the first gene therapy deal the
-
UniQure gets speedy US review for Huntington’s gene therapy
vector carrying gene designed to reduce levels of an overexpressed protein in Huntington’s disease. ... We are nearing the initiation of a phase 1/2 study of AMT-130, the first one-time administered AAV gene therapy to enter clinical testing for
-
Editas CEO exits the CRISPR firm ahead of first clinical trial
EDIT-101 is also expected to become the of Editas’ gene-editing medicines to start clinical testing, as the company recently got approval for an Investigational New Drug (IND) application for ... EDIT-101 is designed to be delivered directly into the
-
GSK: we won’t be splitting up any time soon
Also announced was a major new alliance with consumer gene testing company 23andMe.
-
Spinraza keeps Biogen buoyant ahead of Alzheimer’s data
one-off gene therapy in testing by Novartis/Avexis. ... Another candidate for SMA has hit a snag, however, with the FDA applying a clinical hold on a gene therapy candidate developed in partnership with the University of Pennsylvania, just ahead
More from news
Approximately 1 fully matching, plus 15 partially matching documents found.
Latest Intelligence
-
Cell and gene therapy
And even for allogeneic cell therapies and gene therapies, raw materials and analytical testing costs will also need to be reduced” Davies said. ... As a result, Lonza’s efforts to reduce cell and gene therapy production costs involve logistics, said
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- New study identifies drugs that are safe to use in COVID-19 treatment
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- How COVID-19 is accelerating the threat of antimicrobial resistance
- UK COVID-19 vaccine ‘challenge trials’ could intentionally infect participants with virus
- Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial
- BMS eyes approval for second Opdivo combo in kidney cancer
- Live Webinar: Leveraging Digital Technologies to Create Valuable KOL Engagements & Empower Patients
- Live Webinar: Harnessing Technology to Improve Health and Healthcare
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Lilly’s Verzenio scores a win in early-stage breast cancer
- FDA sets January decision date for Xalkori in ALK-positive lymphoma
- Q&A: Isabel Gibson
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- Surviving cancer: a new era for patients
- Now more than ever, a shift in perspective is needed...
- Crisis? No problem!
- Issues planning & management for pharma spokespeople, by Andrew Smith...
- Are patient recruitment and retention rates rising or falling?
- First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Quick links
Infographics
